Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Key Highlights
- ➤Private placement raised approximately $24.0 million through 20,338,974 shares
- ➤Cash and short-term investments totaled approximately $30.6 million at September 30
- ➤Third-quarter net loss narrowed to approximately $1.0 million from $3.0 million
- ➤Nine-month research and development expenses fell 83% to approximately $1.1 million
- ➤Indaptus plans early-stage research on a neurotechnology sleep-related device
Expert Statements
Junyi Dai, CEO and Chairman of the Board of Indaptus Therapeutics
“Our strategic objective is to position Indaptus for its next phase of growth by actively pursuing innovative opportunities with significant long-term potential and expanding the Company’s strategic focus into promising areas of medical innovation.”
Junyi Dai, CEO and Chairman of the Board of Indaptus Therapeutics
“We believe the successful completion of our approximately $24.0 million private placement provides an important foundation to advance this vision, giving us the financial resources and strategic flexibility to explore new opportunities and build long-term shareholder value.”
Junyi Dai, CEO and Chairman of the Board of Indaptus Therapeutics
“We are particularly excited about the opportunity to explore the potential of an innovative neurotechnology- and neural-network-based device for certain sleep-related conditions.”
Junyi Dai, CEO and Chairman of the Board of Indaptus Therapeutics
“We believe this area represents an intriguing opportunity to investigate novel approaches to addressing unmet needs in sleep-related health.”
Junyi Dai, CEO and Chairman of the Board of Indaptus Therapeutics
“Through early-stage research and preclinical evaluation, we hope to further assess its scientific potential and explore a possible development pathway toward a future FDA submission.”
Junyi Dai, CEO and Chairman of the Board of Indaptus Therapeutics
“Our ambition is to position Indaptus for its next phase of growth by pursuing innovative opportunities with meaningful potential.”
Junyi Dai, CEO and Chairman of the Board of Indaptus Therapeutics
“We intend to move forward with energy and conviction, while maintaining a disciplined approach to capital allocation and focusing our resources on opportunities that we believe can create meaningful long-term value for our shareholders.”
NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, today announced financial results for the third quarter and nine months ended September 30, 2026, and provided a corporate update.
Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board, commented, “Our strategic objective is to position Indaptus for its next phase of growth by actively pursuing innovative opportunities with significant long-term potential and expanding the Company’s strategic focus into promising areas of medical innovation. We believe the successful completion of our approximately $24.0 million private placement provides an important foundation to advance this vision, giving us the financial resources and strategic flexibility to explore new opportunities and build long-term shareholder value.
Get started
Create a free account to read the full story.